
6.4mg Zenrelia for Dogs - Per Tablet
6.4mg Zenrelia is a once-daily, orally administered tablet containing ilunocitinib, a Janus kinase (JAK) inhibitor indicated for dogs from 12 months of age and weighing at least 3kg. It is formulated as a small, unflavoured film-coated tablet designed for ease of administration with or without food, with consistent dosing recommended at the same time each day.
Zenrelia works by inhibiting Janus kinase pathways involved in the inflammatory and pruritic signalling cascade. By targeting these pathways, Zenrelia reduces the biochemical processes that result in the characteristic itch and inflammation of allergic and atopic dermatitis. Following oral administration, it is rapidly absorbed, with visible improvements often appearing within 24 hours. While some dogs respond immediately, a full assessment of response should wait at least one week, with most showing notable improvement in itch and skin condition by two to four weeks.
Zenrelia 6.4mg is appropriate for use from the first veterinary consultation through diagnostic work-up and into long-term maintenance. Its simple, once-daily dosing implies that caregivers can begin treatment before a full diagnosis of atopic dermatitis, helping manage symptoms while underlying causes are explored and addressed.
VETERINARY PRESCRIPTION REQUIRED